Liposome encapsulated mitoxantrone

Drug Profile

Liposome encapsulated mitoxantrone

Alternative Names: LEM; LEM ETU; Liposomal mitoxantrone; Mitoxantrone liposomal

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator NeoPharm Inc
  • Class Anthraquinones; Antineoplastics
  • Mechanism of Action DNA inhibitors; DNA topoisomerase inhibitors; Immunosuppressants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Leukaemia; Multiple sclerosis; Solid tumours

Most Recent Events

  • 09 Jun 2003 Data presented at the 39th Annual Meeting of the American Society of Clinical Oncology have been added to the adverse events and Cancer therapeutic trials section ,
  • 02 Dec 2002 A preclinical study has been added to the pharmacokinetics section
  • 26 Nov 2002 A study has been added to the adverse events and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top